vs
南玻集团（CSGS）与Guardant Health, Inc.（GH）财务数据对比。点击上方公司名可切换其他公司
南玻集团的季度营收约是Guardant Health, Inc.的1.1倍（$323.1M vs $281.3M），南玻集团净利率更高（2.2% vs -45.7%，领先47.9%），Guardant Health, Inc.同比增速更快（39.4% vs 2.0%），南玻集团自由现金流更多（$55.8M vs $-54.2M），过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 4.6%）
中国南玻集团股份有限公司是中国规模最大的建筑玻璃生产商，业务涵盖浮法玻璃、建筑玻璃、显示玻璃、汽车玻璃、镀膜玻璃、镜子、彩滤玻璃、太阳能玻璃及节能玻璃等各类玻璃产品的研发、生产与销售，产品广泛应用于建筑、消费电子、新能源汽车、光伏等多个领域。
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
CSGS vs GH — 直观对比
营收规模更大
CSGS
是对方的1.1倍
$281.3M
营收增速更快
GH
高出37.3%
2.0%
净利率更高
CSGS
高出47.9%
-45.7%
自由现金流更多
CSGS
多$110.0M
$-54.2M
两年增速更快
GH
近两年复合增速
4.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $323.1M | $281.3M |
| 净利润 | $7.0M | $-128.5M |
| 毛利率 | 50.0% | 64.6% |
| 营业利润率 | 9.0% | -43.0% |
| 净利率 | 2.2% | -45.7% |
| 营收同比 | 2.0% | 39.4% |
| 净利润同比 | -79.7% | -15.8% |
| 每股收益（稀释后） | $0.24 | $-1.01 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGSGH
| Q4 25 | $323.1M | $281.3M | ||
| Q3 25 | $303.6M | $265.2M | ||
| Q2 25 | $297.1M | $232.1M | ||
| Q1 25 | $299.5M | $203.5M | ||
| Q4 24 | $316.7M | $201.8M | ||
| Q3 24 | $295.1M | $191.5M | ||
| Q2 24 | $290.3M | $177.2M | ||
| Q1 24 | $295.1M | $168.5M |
净利润CSGSGH
| Q4 25 | $7.0M | $-128.5M | ||
| Q3 25 | $20.5M | $-92.7M | ||
| Q2 25 | $12.3M | $-99.9M | ||
| Q1 25 | $16.1M | $-95.2M | ||
| Q4 24 | $34.5M | $-111.0M | ||
| Q3 24 | $19.1M | $-107.8M | ||
| Q2 24 | $13.8M | $-102.6M | ||
| Q1 24 | $19.5M | $-115.0M |
毛利率CSGSGH
| Q4 25 | 50.0% | 64.6% | ||
| Q3 25 | 48.1% | 64.7% | ||
| Q2 25 | 49.5% | 65.0% | ||
| Q1 25 | 48.4% | 63.3% | ||
| Q4 24 | 51.3% | 61.6% | ||
| Q3 24 | 49.4% | 61.1% | ||
| Q2 24 | 47.3% | 59.1% | ||
| Q1 24 | 46.5% | 61.2% |
营业利润率CSGSGH
| Q4 25 | 9.0% | -43.0% | ||
| Q3 25 | 10.0% | -37.3% | ||
| Q2 25 | 10.0% | -45.9% | ||
| Q1 25 | 9.8% | -54.6% | ||
| Q4 24 | 13.4% | -62.4% | ||
| Q3 24 | 10.8% | -61.3% | ||
| Q2 24 | 8.8% | -56.8% | ||
| Q1 24 | 10.8% | -59.2% |
净利率CSGSGH
| Q4 25 | 2.2% | -45.7% | ||
| Q3 25 | 6.7% | -35.0% | ||
| Q2 25 | 4.1% | -43.0% | ||
| Q1 25 | 5.4% | -46.8% | ||
| Q4 24 | 10.9% | -55.0% | ||
| Q3 24 | 6.5% | -56.3% | ||
| Q2 24 | 4.8% | -57.9% | ||
| Q1 24 | 6.6% | -68.2% |
每股收益（稀释后）CSGSGH
| Q4 25 | $0.24 | $-1.01 | ||
| Q3 25 | $0.73 | $-0.74 | ||
| Q2 25 | $0.44 | $-0.80 | ||
| Q1 25 | $0.57 | $-0.77 | ||
| Q4 24 | $1.20 | $-0.90 | ||
| Q3 24 | $0.67 | $-0.88 | ||
| Q2 24 | $0.48 | $-0.84 | ||
| Q1 24 | $0.68 | $-0.94 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $180.0M | $378.2M |
| 总债务越低越好 | $539.5M | $1.5B |
| 股东权益账面价值 | $283.7M | $-99.3M |
| 总资产 | $1.5B | $2.0B |
| 负债/权益比越低杠杆越低 | 1.90× | — |
8季度趋势，按日历期对齐
现金及短期投资CSGSGH
| Q4 25 | $180.0M | $378.2M | ||
| Q3 25 | $158.4M | $580.0M | ||
| Q2 25 | $145.9M | $629.1M | ||
| Q1 25 | $136.0M | $698.6M | ||
| Q4 24 | $161.8M | $525.5M | ||
| Q3 24 | $118.4M | $585.0M | ||
| Q2 24 | $110.4M | $933.7M | ||
| Q1 24 | $120.8M | $1.0B |
总债务CSGSGH
| Q4 25 | $539.5M | $1.5B | ||
| Q3 25 | $538.6M | $1.1B | ||
| Q2 25 | $537.8M | $1.1B | ||
| Q1 25 | $537.6M | $1.1B | ||
| Q4 24 | $538.5M | $1.1B | ||
| Q3 24 | $539.5M | — | ||
| Q2 24 | $540.5M | — | ||
| Q1 24 | $541.5M | — |
股东权益CSGSGH
| Q4 25 | $283.7M | $-99.3M | ||
| Q3 25 | $289.5M | $-354.5M | ||
| Q2 25 | $290.7M | $-305.5M | ||
| Q1 25 | $283.1M | $-250.8M | ||
| Q4 24 | $282.6M | $-139.6M | ||
| Q3 24 | $288.4M | $-60.1M | ||
| Q2 24 | $273.3M | $-1.6M | ||
| Q1 24 | $269.3M | $68.3M |
总资产CSGSGH
| Q4 25 | $1.5B | $2.0B | ||
| Q3 25 | $1.5B | $1.3B | ||
| Q2 25 | $1.4B | $1.3B | ||
| Q1 25 | $1.4B | $1.3B | ||
| Q4 24 | $1.5B | $1.5B | ||
| Q3 24 | $1.4B | $1.5B | ||
| Q2 24 | $1.4B | $1.6B | ||
| Q1 24 | $1.3B | $1.7B |
负债/权益比CSGSGH
| Q4 25 | 1.90× | — | ||
| Q3 25 | 1.86× | — | ||
| Q2 25 | 1.85× | — | ||
| Q1 25 | 1.90× | — | ||
| Q4 24 | 1.91× | — | ||
| Q3 24 | 1.87× | — | ||
| Q2 24 | 1.98× | — | ||
| Q1 24 | 2.01× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $59.2M | $-26.4M |
| 自由现金流经营现金流 - 资本支出 | $55.8M | $-54.2M |
| 自由现金流率自由现金流/营收 | 17.3% | -19.3% |
| 资本支出强度资本支出/营收 | 1.1% | 9.9% |
| 现金转化率经营现金流/净利润 | 8.46× | — |
| 过去12个月自由现金流最近4个季度 | $141.4M | $-233.1M |
8季度趋势，按日历期对齐
经营现金流CSGSGH
| Q4 25 | $59.2M | $-26.4M | ||
| Q3 25 | $47.9M | $-35.4M | ||
| Q2 25 | $37.3M | $-60.3M | ||
| Q1 25 | $11.5M | $-62.7M | ||
| Q4 24 | $82.5M | $-64.5M | ||
| Q3 24 | $39.5M | $-51.1M | ||
| Q2 24 | $43.1M | $-94.0M | ||
| Q1 24 | $-29.4M | $-30.3M |
自由现金流CSGSGH
| Q4 25 | $55.8M | $-54.2M | ||
| Q3 25 | $43.9M | $-45.8M | ||
| Q2 25 | $34.6M | $-65.9M | ||
| Q1 25 | $7.1M | $-67.1M | ||
| Q4 24 | $76.6M | $-83.4M | ||
| Q3 24 | $32.0M | $-55.3M | ||
| Q2 24 | $38.8M | $-99.1M | ||
| Q1 24 | $-34.1M | $-37.2M |
自由现金流率CSGSGH
| Q4 25 | 17.3% | -19.3% | ||
| Q3 25 | 14.5% | -17.3% | ||
| Q2 25 | 11.6% | -28.4% | ||
| Q1 25 | 2.4% | -33.0% | ||
| Q4 24 | 24.2% | -41.3% | ||
| Q3 24 | 10.8% | -28.9% | ||
| Q2 24 | 13.4% | -55.9% | ||
| Q1 24 | -11.6% | -22.1% |
资本支出强度CSGSGH
| Q4 25 | 1.1% | 9.9% | ||
| Q3 25 | 1.3% | 3.9% | ||
| Q2 25 | 0.9% | 2.4% | ||
| Q1 25 | 1.5% | 2.2% | ||
| Q4 24 | 1.9% | 9.4% | ||
| Q3 24 | 2.5% | 2.2% | ||
| Q2 24 | 1.5% | 2.9% | ||
| Q1 24 | 1.6% | 4.1% |
现金转化率CSGSGH
| Q4 25 | 8.46× | — | ||
| Q3 25 | 2.34× | — | ||
| Q2 25 | 3.04× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 2.39× | — | ||
| Q3 24 | 2.07× | — | ||
| Q2 24 | 3.12× | — | ||
| Q1 24 | -1.51× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
